IRVINE, Calif., Aug. 28, 2006 (PRIMEZONE) -- "Last week's headline-grabbing stem cell breakthrough by Advanced Cell Technology, Inc. (OTCBB:ACTC) sent the company's shares skyrocketing upward," stated SmallCap Sentinel analyst D.R. Clark. "But it also brought attention to a sub-group of non-controversial stem cell companies like Medistem Laboratories, Inc. (OTCBB:MDSM).
"Whether you agree with funding limitations or other restrictions on stem cell research, the reality is that for the most part, companies with research processes unencumbered by glaring ethical constraints may find themselves in vogue," Clark noted. "And if the kind of headlines we saw last week start coming from non-controversial companies such as Medistem Laboratories (OTCBB:MDSM), the political arguments might someday be moot."
Medistem Laboratories is an innovative biotechnology company committed to the creation, licensing and commercialization of advanced medical therapies based on non-controversial adult stem cells. The company intends to use adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, which the company believes to be non-controversial sources of stem cells. The company's business strategy calls for the establishment of a series of adult stem cell banks and clinics around the world to deliver unprecedented, next-generation adult stem cell therapies.
For more information on Medistem visit: http://www.trilogy-capital.com/tcp/medistem/.
The informational report "Looking at the Political Impact on Stem Cell Research" has been made available via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address Medistem, Advanced Cell Technology, Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN).
Individuals may register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 previously by Advanced Cell Technology, Inc. for preparation and distribution of reports and other advertising services. MP has been paid $1,500 by Medistem for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.